Compensation in pre-synaptic dopaminergic function following nigrostriatal damage in primates

Area of Science:

• Neuroscience
• Neuropharmacology
• Primate Models

Background:

• Parkinson's disease (PD) symptoms manifest only after substantial striatal dopamine depletion (70-80%).
• Pre-synaptic dopaminergic mechanisms play a crucial role in compensating for neurodegeneration.

Purpose of the Study:

• To investigate the adaptive changes in pre-synaptic dopaminergic markers and function following nigrostriatal damage in primates.
• To understand how these adaptations contribute to the delayed onset of Parkinson's disease symptoms.

Main Methods:

• MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) treatment to induce nigrostriatal damage in primates.
• Assessment of dopamine levels, nicotinic receptors, tyrosine hydroxylase, and vesicular monoamine transporter expression.
• Measurement of striatal dopamine uptake, transporter sites, and evoked dopamine release (nicotine- and K(+)-evoked) from synaptosomes.

Main Results:

• MPTP caused graded dopamine loss, most severe in the dorsolateral striatum (95-99%).
• Dopamine uptake, transporter sites, and receptor expression showed less severe declines than dopamine levels.
• Nicotine-evoked dopamine release remained relatively intact in the ventromedial striatum, indicating preserved release processes.

Conclusions:

• Compensatory mechanisms, particularly preserved release processes in the ventromedial striatum, help maintain function despite significant dopamine loss.
• These adaptations explain the late emergence of clinical symptoms in Parkinson's disease.
• Pre-synaptic adaptations are critical for buffering dopamine depletion before symptom manifestation.